Clinical trials: Irritable Bowel
Irritable Bowel Syndrome
Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)
The purpose of this study is to determine the efficacy, safety, and tolerability of different doses of eluxadoline (JNJ-27018966) compared with placebo in the treatment of participants with diarrhea-predominant irritable bowel…
- Trial name
- NCT01553747
- Testing
- Eluxadoline
- Where
- 253 sites in United States, Canada and 2 more
- Volunteers
- 1,146 people
- Sponsor
- Furiex Pharmaceuticals, Inc
Irritable Bowel Syndrome (IBS)
Feasibility and Reproducibility of Barostat Assessments of Colorectal Sensation During Colorectal Distention and Its Pharmacological Modulation Using Octreotide
This study is designed to provide information on feasibility and reproducibility of barostat assessments of colorectal sensory functions and compliance and their pharmacological modulation
- Trial name
- NCT00584298
- Testing
- SMS995
- Where
- 7 sites in United States, Canada and 2 more
- Volunteers
- 50 people
- Sponsor
- Novartis
Functional Gastrointestinal Disorders Such as Irritable Bowel Syndrome and Functional Dyspepsia, Irritable Bowel Syndrome
A Pharmacy-based Observational Study to Learn More About Iberogast Advance in the Real-world Setting
This is an observational study in which data from people with functional gastrointestinal disorders who decide on their own or by recommendation of their doctors or pharmacists to take Iberogast Advance are collected and studied.
- Conditions
- Functional Gastrointestinal Disorders Such as Irritable Bowel Syndrome and Functional Dyspepsia, Irritable Bowel Syndrome, Functional Dyspepsia
- Trial name
- NCT05389709
- Testing
- Iberogast (STW5-II, BAY98-7410)
- Where
- Germany
- Volunteers
- 184 people
- Sponsor
- Bayer
Irritable Bowel Syndrome With Constipation (IBS-C)
Phase III Study to Evaluate the Efficacy and Safety of ASP0456 in Patients With Constipation Predominant Irritable Bowel Syndrome
The objective of this study is to evaluate the efficacy and safety of ASP0456 in patients with constipation predominant irritable bowel syndrome (IBS-C).
- Trial name
- NCT02316899
- Testing
- linaclotide
- Where
- 61 sites in Japan
- Volunteers
- 500 people
- Sponsor
- Astellas Pharma Inc
Peristomal Skin Complication
Preliminary Evaluation of CASTLE Barrier Prototype UK
The purpose of this study is to provide preliminary assessment of the safety and performance of a novel barrier formulation (CASTLE) in a small population of subjects with irritated peristomal skin.
- Trial name
- NCT01530087
- Testing
- CASTLE barrier
- Where
- United Kingdom
- Volunteers
- 3 people
- Sponsor
- Hollister Incorporated
Irritable Bowel Syndrome (IBS)
Effect of HMOs as Nutritional Support for Normal Bowel Movements in IBS Patients
This is an open labeled, one-armed real-world study in IBS-patients. All participants will receive active treatment for 12 weeks.
- Trial name
- GRIPS (NCT03550742)
- Testing
- Fuco-N-Tetraose
- Where
- United States
- Volunteers
- 317 people
- Sponsor
- Glycom, Inc.
Irritable Bowel Syndrome
Efficacy Evaluation of a Commercial Preparation Containing Lactobacillus Casei DG on the Reduction of the Painful Symptoms Related to the Irritable Bowel Syndrome (IBS). A Pilot Clinical Study
The purpose of this study is to evaluate the efficacy of a treatment with Lactobacillus casei DG in the reduction of the painful symptoms in patients affected by irritable bowel syndrome.
- Trial name
- NCT02077699
- Testing
- Lactobacillus casei DG
- Where
- Italy
- Volunteers
- 10 people
- Sponsor
- SOFAR S.p.A.
Irritable Bowel Syndrome
Ibodutant for Relief of Irritable Bowel Syndrome (IRIS)
The purpose of the study is to evaluate the benefit of treatment with oral dose of Ibodutant (code: MEN 15596) on IBS symptoms and the safety and tolerability of this therapy.
- Trial name
- IRIS (NCT00761007)
- Testing
- Ibodutant
- Where
- 6 sites in Denmark, Germany and 4 more
- Volunteers
- 554 people
- Sponsor
- Menarini Group
Irritable Bowel Syndrome With Constipation (IBS-C)
A Study of the Effect of SYN-010 on Subjects With IBS-C
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multi-Dose Study of the Effect of Two Dosage Strengths of SYN-010 Compared with Placebo on Breath Methane Production in Breath Methane-Positive Subjects with…
- Trial name
- NCT02495623
- Testing
- SYN-010 21 mg, SYN-010 42 mg
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Theriva Biologics, Inc.
Crohn's Disease
Long-term Safety Study of Brodalumab in Adults With Crohn's Disease
The purpose of this study is to evaluate the safety and efficacy of long-term treatment with brodalumab in adults with Crohn's disease.
- Trial name
- NCT01199302
- Testing
- Brodalumab
- Where
- 34 sites in United States, Australia and 6 more
- Volunteers
- 67 people
- Sponsor
- Amgen
Irritable Bowel Syndrome (IBS)
A Phase 2, Multi-center Study to Evaluate the Efficacy and Safety of ONO-2952 in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
The objective of this study is to explore efficacy, safety and tolerability of ONO-2952 in female subjects with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D).
- Trial name
- RESTORE (NCT01844180)
- Testing
- ONO-2952
- Where
- 48 sites in United States
- Volunteers
- 200 people
- Sponsor
- Ono Pharma USA Inc
Irritable Bowel Syndrome
EFESO - EFficacy Enterogermina Small Intestinal Bacterial Overgrowth
Primary objective: to assess the efficacy of Bacillus clausii versus metronidazole in the eradication of the small intestinal bacterial overgrowth, 30 days after the end of treatment.
- Trial name
- NCT00331994
- Testing
- Bacillus clausii, Metronidazole
- Where
- Italy
- Volunteers
- 250 people
- Sponsor
- Sanofi
Irritable Bowel Syndrome, Constipation
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C)
The purpose of this study is to evaluate how well brenipatide (LY3537031) is tolerated what side effects may occur, and the safety and efficacy in participants with Irritable Bowel Syndrome-Constipation (IBS-C).
- Trial name
- RENEW-IBS-C (NCT07545772)
- Testing
- LY3537031
- Where
- 70 sites in United States, Belgium and 6 more
- Volunteers
- 342 people
- Sponsor
- Eli Lilly and Company
Irritable Bowel Syndrome
Effect of Probiotic Supplement on Bowel Function
The purpose of this study is to analyse the effect of probiotic supplement on symptoms of irritable bowel syndrome.
- Trial name
- IBS2 (NCT01475929)
- Testing
- Probiotic supplement
- Where
- Finland
- Volunteers
- 149 people, healthy volunteers welcome
- Sponsor
- Danisco
Chronic Constipation (CC) (Excluding Constipation Due to Organic Diseases), Irritable Bowel Syndrome With Constipation (IBS-C)
Post-marketing Surveillance of Linaclotide Tablet in Patients With Irritable Bowel Syndrome With Constipation or Chronic Constipation (Excluding Constipation Due to Organic Diseases)
The objective of this study is to evaluate the long-term safety and efficacy of linaclotide in post-marketing use.
- Trial name
- NCT03471728
- Testing
- linaclotide
- Where
- 47 sites in Japan
- Volunteers
- 2,475 people
- Sponsor
- Astellas Pharma Inc
Irritable Bowel Syndrome
Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)
The purpose of this study is to determine the efficacy, safety, and tolerability of different doses of eluxadoline (JNJ-27018966) compared with placebo in the treatment of participants with diarrhea-predominant irritable bowel…
- Trial name
- NCT01553591
- Testing
- Eluxadoline
- Where
- 283 sites in United States, Canada and 1 more
- Volunteers
- 1,282 people
- Sponsor
- Furiex Pharmaceuticals, Inc
Irritable Bowel Syndrome
Study of LX1031 in Subjects With Non-Constipating Irritable Bowel Syndrome
The purpose of the study is to evaluate the safety, tolerability, and effectiveness of LX1031 versus a placebo control in subjects with non-constipating irritable bowel syndrome.
- Trial name
- NCT00813098
- Testing
- LX1031 High Dose, LX1031 Low Dose
- Where
- 36 sites in United States
- Volunteers
- 155 people
- Sponsor
- Lexicon Pharmaceuticals
Small Intestinal Bacterial Overgrowth, SIBO
The Safety And Efficacy Of A Probiotic Intervention On Lactulose Hydrogen Breath Test-Positive Patients And Related Gastrointestinal Symptoms
The goal of this study is to test the effect of a probiotic formulation on gastrointestinal symptoms, gut and small intestine microbiota in participants suffering from small intestinal bacterial overgrowth (SIBO).
- Trial name
- NCT06317441
- Testing
- Probiotic
- Where
- Canada
- Volunteers
- 105 people
- Sponsor
- Nimble Science Ltd.
Irritable Bowel Syndrome
Effect of Probiotic Supplement in Alleviating Functional Gastrointestinal Symptoms
The purpose of this study is to analyse the effect of a probiotic supplement on functional intestinal symptoms among subjects diagnosed with irritable bowel syndrome (IBS).
- Trial name
- NCT01728610
- Testing
- Probiotic (Active high), Probiotic (Active low)
- Where
- 2 sites in Finland
- Volunteers
- 391 people, healthy volunteers welcome
- Sponsor
- Danisco
Irritable Bowel Syndrome With Diarrhea
52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Irritable Bowel Syndrome with diarrhoea (IBS-D) is a functional gastrointestinal disorder characterised by chronic or recurrent abdominal pain or discomfort and diarrhoea.
- Trial name
- IRIS-4 (NCT02120027)
- Testing
- Ibodutant 10 mg
- Where
- 139 sites in United States, Czechia and 7 more
- Volunteers
- 558 people
- Sponsor
- Menarini Group